Gill Awards
Gill Award Nominations
Nominations currently closed. Nominations will open soon for 2027.
The Gill Heart and Vascular Institute Award for Outstanding Contributions to Cardiovascular Research
Recognizing notable and life-long achievements in research that have had a sustained impact on understanding cardiovascular biology and disease and/or that have changed the standard of cardiovascular clinical care.
The award recipient will present their body of work at the annual Cardiovascular Research Day in 2027.
2026 Award Recipient
Gill Heart and Vascular Institute Outstanding Contributions to Cardiovascular Research Award
by Ryan Wilhoit
Alan Remaley, MD, PhD
Senior Investigator,
Lipoprotein Metabolism
National Heart, Lung, and Blood Institute (NHLBI)
About Dr. Remaley
Alan T. Remaley, M.D., Ph.D., is the section chief of the Lipoprotein Metabolism Laboratory in the Translational Vascular Medicine Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, MD. He is also a senior staff member of the Department of Laboratory Medicine at the National Institutes of Health Clinical Center. Dr. Remaley received his B.S. in Biochemistry and Chemistry from the University of Pittsburgh in 1981. He received in 1987 a M.D. and Ph.D. (Biochemistry) degree from the University of Pittsburgh and completed in 1990 a residency in Clinical Pathology at the University of Pennsylvania. He did a post-doctoral fellowship with Dr. Bryan Brewer at NHLBI from 1990-1995. He has been the recipient of many awards for his research and has published over 500 papers in the field of lipoprotein metabolism and cardiovascular disease. He is an inventor on multiple patents related to new therapeutic agents and diagnostic tests for cardiovascular disease. He has made important contributions to the field of High-density lipoprotein metabolism, particularly related to the mechanism of cholesterol efflux by the ABCA1 transporter and has developed apoA-I mimetic peptides and recombinant Lecithin:Cholesterol acyl transferase into therapies, which have been tested in early-stage clinical trials. More recently he has expanded his research into Low-density lipoproteins (LDL), the main driver of atherosclerosis and cardiovascular disease. He has developed an equation, which is widely used for estimating the cholesterol content of LDL, and described the first high-resolution structure of APOB100, the main protein constituent of LDL and the ligand for the removal of LDL from the circulation by its receptor.
About Dr. Remaley
Alan T. Remaley, M.D., Ph.D., is the section chief of the Lipoprotein Metabolism Laboratory in the Translational Vascular Medicine Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, MD. He is also a senior staff member of the Department of Laboratory Medicine at the National Institutes of Health Clinical Center. Dr. Remaley received his B.S. in Biochemistry and Chemistry from the University of Pittsburgh in 1981. He received in 1987 a M.D. and Ph.D. (Biochemistry) degree from the University of Pittsburgh and completed in 1990 a residency in Clinical Pathology at the University of Pennsylvania. He did a post-doctoral fellowship with Dr. Bryan Brewer at NHLBI from 1990-1995. He has been the recipient of many awards for his research and has published over 500 papers in the field of lipoprotein metabolism and cardiovascular disease. He is an inventor on multiple patents related to new therapeutic agents and diagnostic tests for cardiovascular disease. He has made important contributions to the field of High-density lipoprotein metabolism, particularly related to the mechanism of cholesterol efflux by the ABCA1 transporter and has developed apoA-I mimetic peptides and recombinant Lecithin:Cholesterol acyl transferase into therapies, which have been tested in early-stage clinical trials. More recently he has expanded his research into Low-density lipoproteins (LDL), the main driver of atherosclerosis and cardiovascular disease. He has developed an equation, which is widely used for estimating the cholesterol content of LDL, and described the first high-resolution structure of APOB100, the main protein constituent of LDL and the ligand for the removal of LDL from the circulation by its receptor.
| Gill Award Committee | |
|---|---|
| Ivor Benjamin, MD Director, Cardiovascular Center Medical College of Wisconsin | Anthony Demaria, MD Professor, Medicine UC San Diego |
| Kim Eagle, MD Director, Frankel Cardiovascular Center University of Michigan | Jane Freedman, MD Director, Division of Cardiovascular Medicine Vanderbilt University |
| Stan Hazen, MD, PhD Chair, Cardiovascular and Metabolic Sciences Cleveland Clinic | Joseph Hill, MD, PhD Division Chief, Cardiology UT Southwestern Medical Center |
| Peter Libby, MD Professor, Medicine Brigham and Women’s Hospital | Elizabeth McNally, MD, PhD Director, Center for Genetic Medicine Northwestern University |
| Dianna Milewicz, MD, PhD Vice Chair, Medical Genetics UT Health Sciences Center at Houston | Steven Nissen, MD Professor, Cardiovascular Medicine Cleveland Clinic |
| Peter Liu, MD Chief Scientific Officer University of Ottawa Heart Institute | Ann Marie Schmidt, MD Professor, Department of Medicine New York University |
| Clyde Yancy, MD Chief, Cardiology Northwestern University |